These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Haag P; Viktorsson K; Lindberg ML; Kanter L; Lewensohn R; Stenke L Exp Hematol; 2009 Jun; 37(6):755-66. PubMed ID: 19463775 [TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Walter RB; Raden BW; Hong TC; Flowers DA; Bernstein ID; Linenberger ML Blood; 2003 Aug; 102(4):1466-73. PubMed ID: 12689934 [TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Rutella S; Bonanno G; Procoli A; Mariotti A; Lucia MB; Contemi AM; Cauda R; Fianchi L; Scambia G; Pagano L; Leone G Exp Hematol; 2006 Jan; 34(1):54-65. PubMed ID: 16413391 [TBL] [Abstract][Full Text] [Related]
8. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Matsui H; Takeshita A; Naito K; Shinjo K; Shigeno K; Maekawa M; Yamakawa Y; Tanimoto M; Kobayashi M; Ohnishi K; Ohno R Leukemia; 2002 May; 16(5):813-9. PubMed ID: 11986941 [TBL] [Abstract][Full Text] [Related]
9. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. ten Cate B; Bremer E; de Bruyn M; Bijma T; Samplonius D; Schwemmlein M; Huls G; Fey G; Helfrich W Leukemia; 2009 Aug; 23(8):1389-97. PubMed ID: 19262596 [TBL] [Abstract][Full Text] [Related]
10. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Walter RB; Raden BW; Cronk MR; Bernstein ID; Appelbaum FR; Banker DE Blood; 2004 Jun; 103(11):4276-84. PubMed ID: 14962898 [TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab Ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Voutsadakis IA Anticancer Drugs; 2002 Aug; 13(7):685-92. PubMed ID: 12187324 [TBL] [Abstract][Full Text] [Related]
12. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514 [TBL] [Abstract][Full Text] [Related]
13. An mTORC1/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function. Maimaitili Y; Inase A; Miyata Y; Kitao A; Mizutani Y; Kakiuchi S; Shimono Y; Saito Y; Sonoki T; Minami H; Matsuoka H Leuk Res; 2018 Nov; 74():68-74. PubMed ID: 30300823 [TBL] [Abstract][Full Text] [Related]
14. Nursing implications of mylotarg: a novel antibody-targeted chemotherapy for CD33+ acute myeloid leukemia in first relapse. Shannon-Dorcy K Oncol Nurs Forum; 2002 May; 29(4):E52-9. PubMed ID: 12011919 [TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Stadtmauer EA Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Sievers EL Expert Opin Biol Ther; 2001 Sep; 1(5):893-901. PubMed ID: 11728223 [TBL] [Abstract][Full Text] [Related]
17. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. Gaul L; Mandl-Weber S; Baumann P; Emmerich B; Schmidmaier R J Cancer Res Clin Oncol; 2008 Feb; 134(2):245-53. PubMed ID: 17653574 [TBL] [Abstract][Full Text] [Related]
18. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. Rosen DB; Harrington KH; Cordeiro JA; Leung LY; Putta S; Lacayo N; Laszlo GS; Gudgeon CJ; Hogge DE; Hawtin RE; Cesano A; Walter RB PLoS One; 2013; 8(1):e53518. PubMed ID: 23320091 [TBL] [Abstract][Full Text] [Related]
19. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. Dowell JA; Korth-Bradley J; Liu H; King SP; Berger MS J Clin Pharmacol; 2001 Nov; 41(11):1206-14. PubMed ID: 11697753 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]